A5025954248- Multiple Myeloma Research and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Biosimilars and Bioanalytical Methods
- Protein Degradation and Inhibitors
- Synthesis and Biological Evaluation
- Cancer Research and Treatments
- Stress Responses and Cortisol
- Bone health and osteoporosis research
- Hormonal Regulation and Hypertension
- Bone health and treatments
- Spectroscopy Techniques in Biomedical and Chemical Research
- Medical Imaging and Pathology Studies
- Drug-Induced Hepatotoxicity and Protection
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Malaria Research and Control
- Nanoplatforms for cancer theranostics
- Bone and Dental Protein Studies
- Chronic Myeloid Leukemia Treatments
- Advanced Nanomaterials in Catalysis
- Estrogen and related hormone effects
- Medical Imaging Techniques and Applications
- Optical Imaging and Spectroscopy Techniques
- Pharmaceutical Economics and Policy
- Insect Resistance and Genetics
- Infrared Thermography in Medicine
Cytel (United States)
2023-2025
Leiden University Medical Center
2009-2016
Leiden University
2012
Multi diameter single fiber reflectance (MDSFR) spectroscopy is a non-invasive optical technique based on using multiple fibers of different diameters to determine both the reduced scattering coefficient (μs') and parameter γ that related angular distribution scattering, where = (1-g2)/(1-g1) g1 g2 first second moment phase function, respectively. Here we present in vivo MDSFR measurements μs'(λ) γ(λ) their wavelength dependence. performed nineteen mice four tissue types including skin,...
Aim: Despite the availability of novel treatment options for patients with triple-class exposed/refractory multiple myeloma , there is a lack consensus on optimal regimen. A previous unanchored matching-adjusted indirect comparison (MAIC) MagnetisMM-3 ( NCT04649359 ) and LocoMMotion NCT04035226 study reported significant improvements in progression-free survival (PFS) overall (OS) elranatamab versus physician’s choice treatment. Materials & methods: We conducted an updated MAIC based...
To estimate the budget impact of adding elranatamab to US formulary treat adults with RRMM who have received ≥4 prior lines therapy including a proteasome inhibitor, an immunomodulatory drug, and anti-CD38 monoclonal antibody, assess total cost care per month progression-free survival (PFS) between available treatments. An economic model was developed in one-million-member commercial Medicare health plan. Epidemiology data obtained from SEER database large real-world study. Key clinical...
For patients with triple-class exposed/refractory multiple myeloma (TCE/RMM), where effective treatments options are limited, B-cell maturation antigen and CD3-directed bispecific antibodies offer a promising new approach. Teclistamab gained conditional approval in Europe accelerated Food Drug Administration (FDA) based on the MajesTEC-1 trial (NCT03145181). Elranatamab, approved by FDA demonstrated its safety efficacy MagnetisMM-3 (NCT04649359). Given absence of head-to-head trials, an...
For patients with triple-class exposed/refractory multiple myeloma (TCE/R MM), prognosis is poor and effective treatment options are limited. Elranatamab a novel B-cell maturation antigen (BCMA)- CD3-directed bispecific antibody which was approved by the US Food Drug Administration in August 2023 demonstrated safety efficacy TCE/R MM phase 2, single-arm MagnetisMM-3 trial (NCT04649359). To compare effectiveness of elranatamab vs physician's choice (PCT) absence head-to-head comparative data,...
e20038 Background: Elranatamab, a bispecific antibody targeting B-cell maturation antigen on multiple myeloma (MM) cells and CD3 T cells, is being evaluated as monotherapy in the MagnetisMM-3 trial (MM3; NCT04649359) patients with triple-class exposed (TCE) relapsed/refractory MM. While there no standard of care for TCE MM, belantamab mafodotin (belamaf) selinexor plus dexamethasone (sel-dex) are treatment options. LocoMMotion prospective, non-interventional study investigating real-world...
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Elranatamab, a bispecific antibody targeting B-cell maturation antigen on multiple myeloma (MM) cells CD3 T cells, is being evaluated as monotherapy in the MagnetisMM-3 trial (MM3; NCT04649359) patients with triple-class exposed (TCE) relapsed/refractory MM. While there no standard of care for TCE MM, belantamab mafodotin (belamaf) selinexor plus dexamethasone (sel-dex) are treatment options. LocoMMotion prospective,...
Abstract Background: Incomplete tumor resections occur frequently in patients undergoing breast-conserving surgery. As the surgeon can only rely on palpation and visual inspection, real-time visualization of cancer cells during surgery is needed to increase number complete resections. Near-infrared fluorescence (NIRF) imaging using an intra-operative camera system a novel technique assess extent disease Advantages NIRF light (700-900 nm) include high tissue penetration up several centimeters...